ADCT ADC TherapeuticsWatchlist
About ADC Therapeutics Company
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
ABBV.US (ABBV.US) spent $10 billion to acquire Immunogen (IMGN.US) ADC drug developers, and most of the stock prices of drug developers rose
Immunogen closed nearly 83% higher on Thursday and AbbVie closed nearly 3% higher. Shares of other biotech companies developing ADC drugs also rose.
AbbVie-Immunogen Buyout Deal Lifts ADC-focused Biotechs
Analyst Expectations for ADC Therapeutics's Future
Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings22000Last 30D100001M Ago010002M